Nkarta is a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Co. has two product candidates, NKX101 and NKX019. Both product candidates were generated using Co.'s NK cell engineering platform. NKX101 is designed to improve the power of innate NK biology to detect and kill cancerous cells. NKX019 is based on the ability to treat a variety of B-cell malignancies by targeting the CD19 antigen that is found on these types of cancerous cells, where CD19-targeted engineered NK cells, T cells and monoclonal antibodies have demonstrated clinical activity. The NKTX stock yearly return is shown above.
The yearly return on the NKTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NKTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|